Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$28.05 USD
-0.17 (-0.60%)
Updated Oct 17, 2024 03:59 PM ET
After-Market: $28.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.05 USD
-0.17 (-0.60%)
Updated Oct 17, 2024 03:59 PM ET
After-Market: $28.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Finance Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
What Makes Royalty Pharma (RPRX) a New Buy Stock
by Zacks Equity Research
Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.
Royalty Pharma (RPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.05% and 1.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q2 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
MVB Financial (MVBF) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
MVB Financial (MVBF) delivered earnings and revenue surprises of -22.50% and 9.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Royalty Pharma (RPRX) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 50-Day simple moving average, good things could be on the horizon. How should investors react?
How to Find Strong Finance Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
by Zacks Equity Research
Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
by Zacks Equity Research
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.08% and 6.79%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Crescent Capital BDC (CCAP) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Crescent Capital BDC (CCAP) delivered earnings and revenue surprises of 6.78% and 4.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Royalty Pharma (RPRX)
by Zacks Equity Research
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Here's What to Expect From Assurant's (AIZ) Q1 Earnings
by Zacks Equity Research
Assurant's (AIZ) first-quarter performance is likely to have benefited from higher yields in fixed maturity securities, lender-placed average insured values and organic growth across all products.
Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.